Upfront genotyping of DPYD∗2A to individualize fluoropyrimidine therapy: A safety and cost analysis

Journal of Clinical Oncology

Volumn 34, Issue 3, 2016, Pages 227-234

  Deenen, Maarten J ^a   Meulendijks, Didier ^a   Cats, Annemieke ^a   Sechterberger, Marjolein K ^a   Severens, Johan L ^c   Boot, Henk ^a   Smits, Paul H ^b   Rosing, Hilde ^a   Mandigers, Caroline M P W ^d   Soesan, Marcel ^b   Beijnen, Jos H ^a,e   Schellens, Jan H M ^a,e  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROPYRIMIDINE DEHYDROGENASE 2A; FLUOROPYRIMIDINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG SAFETY; ENZYME ACTIVITY; FEASIBILITY STUDY; FEMALE; GENETIC SCREENING; GENOTYPE; HAND FOOT SYNDROME; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; VERY ELDERLY; WILD TYPE; YOUNG ADULT; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COST; ECONOMICS; ENZYMOLOGY; GENETICS; GENOTYPING TECHNIQUE; MIDDLE AGED; NETHERLANDS; PERSONALIZED MEDICINE; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COSTS AND COST ANALYSIS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; GENETIC TESTING; GENOTYPING TECHNIQUES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PRECISION MEDICINE; PROSPECTIVE STUDIES; PYRIMIDINES; YOUNG ADULT;

EID: 84955444392     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.1325     Document Type: Article

References (39)

1. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19: 2282-2292, 2001
2. Koopman M, Antonini NF, Douma J, et al: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 370:135-142, 2007
3. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001
4. Tuchman M, Stoeckeler JS, Kiang DT, et al: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313:245-249, 1985
5. Heggie GD, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206, 1987
6. Mattison LK, Fourie J, Desmond RA, et al: Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 12:5491-5495, 2006
7. Van Kuilenburg AB, Muller EW, Haasjes J, et al: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7:1149-1153, 2001
8. Offer SM, Wegner NJ, Fossum C, et al: Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 73:1958-1968, 2013
9. Vreken P, Van Kuilenburg AB, Meinsma R, et al: A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 19:645-654, 1996
10. Ezzeldin H, Johnson MR, Okamoto Y, et al: Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 9:3021-3028, 2003
11. Blasco H, Boisdron-Celle M, Bougnoux P, et al: A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. Br J Clin Pharmacol 65:966-970, 2008
12. Saif MW, Ezzeldin H, Vance K, et al: DPYD∗2A mutation: The most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 60:503-507, 2007
13. Steiner M, Seule M, Steiner B, et al: 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: Report of a case. J Clin Pathol 58:553-555, 2005
14. Capitain O, Boisdron-Celle M, Poirier AL, et al: The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J 8:256-267, 2008
15. Deenen MJ, Tol J, Burylo AM, et al: Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 17:3455-3468, 2011
16. Braun MS, Richman SD, Thompson L, et al: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trial. J Clin Oncol 27:5519-5528, 2009
17. McLeod HL, Sargent DJ, Marsh S, et al: Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup trial N9741. J Clin Oncol 28:3227-3233, 2010
18. Magné N, Etienne-Grimaldi MC, Cals L, et al: Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol 64:237-240, 2007
19. Raida M, Schwabe W, Häusler P, et al: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 7:2832-2839, 2001
20. Schwab M, Zanger UM, Marx C, et al: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26:2131-2138, 2008
21. Boisdron-Celle M, Remaud G, Traore S, et al: 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249:271-282, 2007
22. Largillier R, Etienne-Grimaldi MC, Formento JL, et al: Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 12:5496-5502, 2006
23. Morel A, Boisdron-Celle M, Fey L, et al: Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5:2895-2904, 2006
24. Terrazzino S, Cargnin S, Del Re M, et al: DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: A meta-analysis. Pharmacogenomics 14:1255-1272, 2013
25. Rosmarin D, Palles C, Church D, et al: Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 32:1031-1039, 2014
26. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
27. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
28. Boige V, Mendiboure J, Pignon JP, et al: Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 28:2556-2564, 2010
29. Cellier P, Leduc B, Martin L, et al: Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. BMC Cancer 11:98, 2011
30. Cerić T, Obralić N, Kapur-Pojskić L, et al: Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-fluorouracil and capecitabine. Bosn J Basic Med Sci 10:133-139, 2010
31. Salgueiro N, Veiga I, Fragoso M, et al: Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med 6:102-107, 2004
32. Sulzyc-Bielicka V, Bińczak-Kuleta A, Pioch W, et al: 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep 60:238-242, 2008
33. Jennings BA, Loke YK, Skinner J, et al: Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One 8:e78053, 2013
34. Deenen MJ, Terpstra WE, Cats A, et al: Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine. Ann Intern Med 153: 767-768, 2010
35. Reigner B, Verweij J, Dirix L, et al: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4:941-948, 1998
36. Twelves C, Glynne-Jones R, Cassidy J, et al: Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 5:1696-1702, 1999
37. Coate L, Cuffe S, Horgan A, et al: Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 28:4029-4037, 2010
38. Magnani E, Farnetti E, Nicoli D, et al: Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: The need for further revision of dose and schedule. Intern Emerg Med 8:417-423, 2013
39. Van Kuilenburg AB, Meijer J, Mul AN, et al: Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 128:529-538, 2010